Eyenovia announces addition to russell 2000® and russell 3000® indexes

New york, june 26, 2023 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), a commercial-stage ophthalmic technology company preparing for the launch of mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the company was added to the small cap russell 2000® and broad market russell 3000® indexes effective today.
EYEN Ratings Summary
EYEN Quant Ranking